DIAZEPAM Drug Interactions
Also known as: Diazepam
Diazepam is a medication in the benzodiazepine class that works by calming the brain and nerves. It is primarily used to treat anxiety disorders, relieve symptoms of acute alcohol withdrawal, and help relax muscles to ease spasms.DIAZEPAM has 11 documented drug interactions in our database, including 4 contraindicated, 7 major, 0 moderate, and 0 minor interactions.
4
Contraindicated
7
Major
0
Moderate
0
Minor
The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may exhibit decreased level of consciousness, hypoventilation, bradycardia, hypotension, and miosis. These effects can be life-threatening and require immediate medical intervention.
Mechanism
Tramadol, an opioid analgesic, and diazepam, a benzodiazepine, both exert central nervous system (CNS) depressant effects. Tramadol's actions are primarily mediated through mu-opioid receptor agonism and inhibition of norepinephrine and serotonin reuptake, while diazepam enhances the effect of the inhibitory neurotransmitter GABA at the GABA-A receptor. Concomitant use leads to an additive and synergistic depression of the CNS, particularly affecting respiratory drive.
Clinical Management
Concomitant use of tramadol and diazepam is generally contraindicated due to the severe risks. If co-administration is unavoidable, it should be reserved for patients for whom alternative treatment options are inadequate, and the lowest effective doses should be used for the shortest possible duration. Patients must be closely monitored for signs of respiratory depression and sedation, and naloxone should be readily available.
Patients may experience profound sedation, respiratory depression, coma, and death. Other symptoms can include severe psychomotor impairment, hypotension, and decreased level of consciousness. The onset of these effects can be rapid and life-threatening.
Mechanism
Both hydromorphone, an opioid agonist, and diazepam, a benzodiazepine, are central nervous system (CNS) depressants. Their co-administration leads to an additive depressant effect on the CNS, particularly on the respiratory drive, leading to profound sedation and respiratory depression. This synergistic action occurs through distinct but converging pathways that reduce neuronal excitability.
Clinical Management
Concomitant use of opioids and benzodiazepines should be avoided whenever possible due to the high risk of severe adverse outcomes, including death. If co-administration is absolutely necessary, use the lowest effective doses for the shortest possible duration, monitor patients closely for respiratory depression and sedation, and ensure naloxone is readily available. Consider alternative treatments that do not involve co-prescribing these classes.
The concurrent use of oxymorphone and diazepam can lead to profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, apnea, hypotension, and psychomotor impairment. This interaction significantly increases the risk of accidental overdose and life-threatening adverse events.
Mechanism
Oxymorphone, an opioid agonist, and diazepam, a benzodiazepine, both depress the central nervous system (CNS). Opioids primarily act on mu-opioid receptors to inhibit GABAergic interneurons, leading to disinhibition of dopamine neurons and respiratory depression. Benzodiazepines enhance the effect of the inhibitory neurotransmitter GABA at the GABA-A receptor, increasing chloride ion influx and hyperpolarizing neurons. The synergistic CNS depressant effects of these two drug classes significantly amplify respiratory depression, sedation, and psychomotor impairment.
Clinical Management
Concomitant use of oxymorphone and diazepam is contraindicated due to the high risk of respiratory depression, profound sedation, coma, and death. If co-administration is unavoidable, which should be rare and only considered when alternative treatment options are inadequate, dosages of both drugs should be reduced, and patients must be closely monitored for signs of respiratory depression and sedation. Naloxone should be readily available, and patients should be educated on the risks.
This combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, and hypotension. The FDA has issued a Black Box Warning highlighting these life-threatening risks.
Mechanism
Tapentadol is an opioid analgesic with mu-opioid receptor agonist activity and norepinephrine reuptake inhibition. Diazepam is a benzodiazepine that enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor. Concomitant use leads to synergistic central nervous system (CNS) depression by acting on different but complementary pathways.
Clinical Management
Concomitant use of tapentadol and diazepam is generally contraindicated due to the high risk of severe adverse outcomes. If co-prescription is absolutely unavoidable, use the lowest effective doses for the shortest possible duration, closely monitor for respiratory depression and sedation, and ensure naloxone is available. Consider alternative non-opioid or non-benzodiazepine treatments.
The concurrent use of buprenorphine and diazepam significantly increases the risk of severe adverse events including profound sedation, respiratory depression, coma, and death. Patients may exhibit somnolence, decreased level of consciousness, bradycardia, hypotension, and hypoventilation. The risk is heightened in opioid-naive individuals or those with underlying respiratory compromise.
Mechanism
Buprenorphine, a partial opioid agonist, and diazepam, a benzodiazepine, both cause central nervous system (CNS) depression. This interaction is primarily pharmacodynamic, as both drugs potentiate the inhibitory effects of gamma-aminobutyric acid (GABA) at different receptor sites, leading to additive CNS and respiratory depressant effects. Buprenorphine's respiratory depressant effects are mediated via mu-opioid receptors, while diazepam enhances GABAergic transmission.
Clinical Management
Concomitant use should generally be avoided due to the significant risks. If co-prescription is absolutely necessary, the lowest effective doses of both medications should be used for the shortest possible duration, with careful monitoring for signs of respiratory depression and sedation. Patients and caregivers must be educated on the risks and symptoms, and naloxone should be considered for at-home use. Gradual dose reduction of one or both agents may be necessary if adverse effects occur.
The combination can lead to profound sedation, respiratory depression (decreased respiratory rate and depth), hypotension, psychomotor impairment, coma, and death. Patients may exhibit somnolence, confusion, dizziness, and difficulty arousing. The onset of these effects can be rapid and severe.
Mechanism
Both fentanyl (an opioid) and diazepam (a benzodiazepine) are central nervous system (CNS) depressants. Fentanyl acts primarily as a mu-opioid receptor agonist, while diazepam enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors. The concomitant use of these agents leads to an additive and synergistic CNS depressant effect, significantly increasing the risk of respiratory depression.
Clinical Management
Concomitant use should generally be avoided due to the high risk. If co-administration is absolutely necessary, use the lowest effective doses for the shortest possible duration, and monitor patients closely for signs of respiratory depression and sedation. Consider alternative treatments that do not interact with CNS depressants. Educate patients and caregivers about the risks and symptoms to watch for.
This combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, apnea, hypotension, and psychomotor impairment. The effects can be additive and life-threatening.
Mechanism
Oxycodone, an opioid agonist, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia, sedation, and respiratory depression. Diazepam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to CNS depression, anxiolysis, and sedation. The synergistic CNS depressant effects of both drugs, particularly on respiratory drive, lead to a heightened risk of adverse outcomes.
Clinical Management
Coadministration should generally be avoided due to the high risk. If absolutely necessary, prescribe the lowest effective doses for the shortest duration possible, and closely monitor patients for signs of respiratory depression and sedation. Educate patients and caregivers on the risks and symptoms of overdose, and consider prescribing naloxone for at-risk patients.
The primary clinical effects include severe respiratory depression, profound sedation, somnolence, coma, and potentially death. Patients may exhibit decreased respiratory rate, shallow breathing, hypoxemia, altered mental status, and unresponsiveness. These effects can occur rapidly and are dose-dependent.
Mechanism
Both morphine (an opioid agonist) and diazepam (a benzodiazepine) are central nervous system (CNS) depressants. Morphine primarily acts on mu-opioid receptors, while diazepam enhances the effect of the inhibitory neurotransmitter GABA at GABA-A receptors. Their combined CNS depressant effects are synergistic, leading to profound and potentially life-threatening respiratory depression and sedation.
Clinical Management
Coadministration should generally be avoided due to the high risk of severe adverse outcomes. If coadministration is absolutely necessary, use the lowest effective doses and shortest possible duration, closely monitor for respiratory depression and sedation, and educate patients and caregivers on the risks. Naloxone and flumazenil should be readily available for emergency reversal.
Concomitant use of oxycodone, an opioid, and diazepam, a benzodiazepine, can lead to profound sedation, respiratory depression, coma, and death. Patients should be closely monitored for these severe adverse effects.
Mechanism
Both oxycodone and diazepam are central nervous system (CNS) depressants. Oxycodone acts as a mu-opioid receptor agonist, while diazepam enhances the effect of the inhibitory neurotransmitter GABA. Their combined CNS depressant effects are additive, leading to increased risk of respiratory depression and sedation.
Clinical Management
Avoid concomitant use if possible. If co-administration is unavoidable, prescribe the lowest effective doses and shortest durations. Closely monitor patients for respiratory depression and sedation, and educate them on the risks.
Concomitant use can lead to profound sedation, respiratory depression, coma, and death. Patients may experience extreme drowsiness, confusion, slowed or difficult breathing, and unresponsiveness. The risk is heightened in patients with pre-existing respiratory compromise or those who are opioid-naive.
Mechanism
Codeine sulfate, an opioid analgesic, primarily acts as a mu-opioid receptor agonist, leading to central nervous system (CNS) depression, including respiratory depression. Diazepam, a benzodiazepine, enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors, also resulting in CNS depression. The synergistic CNS depressant effects of both drugs significantly increase the risk of adverse outcomes.
Clinical Management
Avoid concomitant use of codeine and diazepam whenever possible. If co-prescription is unavoidable, prescribe the lowest effective doses for the shortest duration possible, and closely monitor patients for signs of respiratory depression and sedation. Educate patients and caregivers about the risks and symptoms, and consider prescribing naloxone if appropriate.
The concurrent use of methadone and diazepam can lead to profound sedation, respiratory depression, coma, and death. Patients may exhibit decreased level of consciousness, hypoventilation, pinpoint pupils, and hypotension. The risk of accidental overdose is significantly increased due to the additive depressant effects on vital functions.
Mechanism
Methadone, an opioid agonist, and diazepam, a benzodiazepine, both act as central nervous system (CNS) depressants. Opioids primarily activate mu-opioid receptors, leading to decreased neuronal excitability, while benzodiazepines enhance the effects of GABA at GABA-A receptors, increasing chloride influx and hyperpolarization. The synergistic CNS depressant effects of these two drug classes significantly potentiate respiratory depression, sedation, and psychomotor impairment.
Clinical Management
Avoid co-prescription of methadone and diazepam whenever possible. If co-administration is unavoidable, reduce the dose of one or both drugs, initiate at the lowest effective dose, and titrate slowly. Monitor patients closely for signs of respiratory depression and sedation, and educate them and their caregivers on the risks, including the availability of naloxone.
For complete prescribing information:
View full DIAZEPAM monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.